Daniela Kandioler-Eckersberger

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

Daniela Kandioler-Eckersberger, Christian Ludwig, Margaretha Rudas et al. · PubMed · 2000 · 286 citations

Breast Oncology, Pathology, Positive P53 Ihc +18

Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.

P. Birner, Georg Oberhuber, Josefine Stani et al. · PubMed · 2001 · 184 citations

Contralateral Breast Cancer: Molecular Differentiation Between Metastasis and Second Primary Cancer

Elisabeth Janschek, Daniela Kandioler-Eckersberger, Carmen Ludwig et al. · Breast Cancer Research and Treatment · 2001 · 68 citations

Second Primary Cancer, Breast Oncology, Medicine +8

Multiple chromosomal abnormalities in human liver (pre)neoplasia

Maria Raidl, Christine Pirker, Rolf Schulte‐Hermann et al. · Journal of Hepatology · 2004 · 60 citations

Hepatology, Liver Physiology, Genetics +7

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer

Daniela Kandioler-Eckersberger, S. Kappel, Martina Mittlböck et al. · Journal of Thoracic and Cardiovascular Surgery · 1999 · 60 citations · Full text

Cisplatin-based Neoadjuvant Therapy, Medicine, Pathology +9